LESLIE PACE: Open Payments
NPI 1609004126 · RENO, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,384 in 71 payments from 17 companies in 2025. Trend: 2023 $1,020 · 2024 $1,309 · 2025 $1,384
Food & beverage: $1,384
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 10 | $264 |
| ABBVIE INC. | 16 | $233 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $153 |
| Novo Nordisk Inc | 6 | $152 |
| PFIZER INC. | 8 | $135 |
| Astellas Pharma US Inc | 5 | $93 |
| GlaxoSmithKline, LLC. | 4 | $91 |
| Lundbeck LLC | 2 | $55 |
| Verity Pharmaceuticals Inc. | 2 | $39 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $34 |
Products named: VRAYLAR, BREZTRI, CAPLYTA, Wegovy, NURTEC ODT, Veozah, TRELEGY ELLIPTA, REXULTI.
Industry payments across NV — which companies pay providers there.
